| Symbol | SYRE |
|---|---|
| Name | SPYRE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 805 LAS CIMAS PARKWAY,SUITE 100, AUSTIN, Texas, 78746, United States |
| Telephone | +1 512 942-2935 |
| Fax | — |
| — | |
| Website | https://www.spyre.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001636282 |
| Description | Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23). Additional info from NASDAQ: |
2026-09-01 20:57
📋 HEIDY KING-JONES (Officer) plans to sell 47K shares of SPYRE THERAPEUTICS INC (at $89.33 each, total $4.2M) Filed: Sep 01, 2026 | ID: 008970
Read more
2026-08-25 20:04
(90% Positive) SPYRE THERAPEUTICS, INC. (SYRE) Provides Update on experience for DAS28-CRP)
Read more
2026-08-25 20:01
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
Read more
2026-08-14 18:22
New Form SCHEDULE 13G/A - Spyre Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352655 <b>Size:</b> 11 KB
Read more
2026-08-14 09:11
New Form SCHEDULE 13G/A - Spyre Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001493215-26-000157 <b>Size:</b> 10 KB
Read more
2026-08-11 01:31
Director Albers Jeffrey W. 🟡 adjusted position in 23.0K shares (1 derivative) of Spyre Therapeutics, Inc. (SYRE) at $104.68 ($2.5M) Transaction Date: Aug 07, 2026 | Filing ID: 000102
Read more
2026-08-07 20:39
📋 JEFFREY ALBERS (Director) plans to sell 5K shares of SPYRE THERAPEUTICS INC (at $103.42 each, total $517K) Filed: Aug 07, 2026 | ID: 007821
Read more
2026-08-07 20:39
📋 SESSIONS, LLC (Director) plans to sell 18K shares of SPYRE THERAPEUTICS INC (at $103.42 each, total $1.9M) Filed: Aug 07, 2026 | ID: 007819
Read more
2026-08-04 20:02
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07766005 | A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (T… | Phase2 | Hidradenitis Suppurativa (HS) | Not_Yet_Recruiting | 2026-09-01 | 2028-06-01 | ClinicalTrials.gov |
| NCT07652294 | Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in C… | Phase2 | Ulcerative Colitis | Enrolling_By_Invitation | 2026-06-08 | 2030-01-03 | ClinicalTrials.gov |
| NCT07148414 | A Study of SPY072 in Rheumatic Disease | Phase2 | Rheumatoid Arthritis | Active_Not_Recruiting | 2025-08-21 | 2028-03-31 | ClinicalTrials.gov |
| NCT07012395 | A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Sev… | Phase2 | Ulcerative Colitis | Recruiting | 2025-05-27 | 2028-03-01 | ClinicalTrials.gov |
| NCT06873724 | A Study of SPY003-207 in Healthy Volunteers | Phase1 | Healthy | Active_Not_Recruiting | 2025-03-10 | 2026-11-18 | ClinicalTrials.gov |
| NCT06672718 | A Study of SPY002-091 in Healthy Volunteers | Phase1 | Healthy | Completed | 2024-11-26 | 2026-08-19 | ClinicalTrials.gov |
| NCT06622070 | A Study of SPY002-072 in Healthy Volunteers | Phase1 | Healthy | Completed | 2024-11-18 | 2026-07-28 | ClinicalTrials.gov |
| NCT06448247 | A Study of SPY001-001 in Healthy Volunteers | Phase1 | Healthy | Completed | 2024-06-06 | 2026-03-10 | ClinicalTrials.gov |
Total clinical trials: 8
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06672718 |
| SPY002-091 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06672718 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06622070 |
| SPY002-072 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06622070 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| bimekizumab | Other | Phase PHASE2 | Hidradenitis Suppurativa (HS) | NOT_YET_RECRUITING | NCT07766005 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa (HS) | NOT_YET_RECRUITING | NCT07766005 |
| SPY072 | Other | Phase PHASE2 | Hidradenitis Suppurativa (HS) | NOT_YET_RECRUITING | NCT07766005 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | ENROLLING_BY_INVITATION | NCT07652294 |
| Placebo | Other | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06672718 |
| SPY002-091 | Other | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06672718 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE1 | Healthy | RECRUITING | NCT06622070 |
| SPY002-072 | Other | Phase PHASE1 | Healthy | RECRUITING | NCT06622070 |
| Placebo | Other | Phase PHASE1 | Healthy | RECRUITING | NCT06672718 |
| SPY002-091 | Other | Phase PHASE1 | Healthy | RECRUITING | NCT06672718 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06873724 |
| SPY003-207 | Other | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06873724 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06448247 |
| SPY001-001 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06448247 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY002-072 | Other | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003 | DRUG | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY002 | DRUG | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY001 | DRUG | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT07012395 |
| SPY003-207 | DRUG | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06873724 |
| SPY002-091 | DRUG | Phase PHASE1 | Healthy | RECRUITING | NCT06672718 |
| SPY002-072 | DRUG | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| Placebo | DRUG | Phase PHASE2 | Rheumatoid Arthritis | RECRUITING | NCT07148414 |
| SPY001-001 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06448247 |
Total products: 330